$AYTU
AYTU BIOPHARMA, INC Stock $aytu

$aytu Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000143774921002627 Filed on February 11, 2021

Income Statement

Concept	2020 Q4	2020 Q2	2019 Q4
Revenue	$15.15M	$14.86M	$3.175M
YoY Change	377.07%	763.95%	76.39%
Cost Of Revenue	$6.251M	$4.570M	$606.0K
YoY Change	931.44%	603.08%	14.35%
Gross Profit	$8.896M	$10.29M	$2.569M
YoY Change	246.29%	861.68%	102.28%
Gross Profit Margin	58.73%	69.25%	80.91%
Selling, General & Admin	$12.85M	$13.64M	$6.516M
YoY Change	97.24%	178.37%	26.77%
% of Gross Profit	144.48%	132.56%	253.65%
Research & Development	$286.0K	$1.500M	$66.68K
YoY Change	328.95%	733.33%	-55.55%
% of Gross Profit	3.21%	14.58%	2.6%
Depreciation & Amortization	$18.00K	$2.470M	$1.290M
YoY Change	-98.6%	225.0%	92.54%
% of Gross Profit	0.2%	24.0%	50.21%
Operating Expenses	$14.47M	$16.73M	$6.583M
YoY Change	119.83%	196.11%	13.11%
Operating Profit	-$5.575M	-$6.440M	-$4.967M
YoY Change	12.24%	40.61%	9.17%
Interest Expense	-$379.0K	-$1.430M	-$447.0K
YoY Change	-15.21%	1091.67%	306.33%
% of Operating Profit
Other Income/Expense, Net	-$3.950M		$4.753M
YoY Change	-183.11%
Pretax Income	-$9.525M	-$3.150M	-$210.0K
YoY Change	4435.71%	-78.32%	-95.49%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$9.525M	-$3.150M	-$214.2K
YoY Change	4345.8%	-78.32%	-95.4%
Net Earnings / Revenue	-62.88%	-21.2%	-6.75%
Basic Earnings Per Share	-$0.72
Diluted Earnings Per Share	-$0.72	-$279.0K	-$120.0K
COMMON SHARES
Basic Shares Outstanding	13.28M
Diluted Shares Outstanding	13.28M

Balance Sheet

Concept	2020 Q4	2020 Q2	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.00M	$48.10M	$5.300M
YoY Change	1069.81%	337.27%	-70.22%
Cash & Equivalents	$62.03M	$48.08M	$5.511M
Short-Term Investments
Other Short-Term Assets	$10.60M	$5.742M	$4.100M
YoY Change	158.51%	341.69%	310.0%
Inventory	$6.571M	$9.999M	$2.500M
Prepaid Expenses		$5.715M
Receivables	$7.001M	$5.633M	$5.200M
Other Receivables	$0.00	$0.00	$1.300M
Total Short-Term Assets	$92.54M	$75.42M	$18.30M
YoY Change	405.67%	389.75%	-16.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$89.66K	$258.5K	$500.0K
YoY Change	-82.07%	29.26%	150.0%
Goodwill	$28.09M	$28.09M
YoY Change
Intangibles		$48.86M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$33.00K	$0.00
YoY Change
Total Long-Term Assets	$74.20M	$77.87M	$56.20M
YoY Change	32.04%	303.48%	175.49%
TOTAL ASSETS
Total Short-Term Assets	$92.54M	$75.42M	$18.30M
Total Long-Term Assets	$74.20M	$77.87M	$56.20M
Total Assets	$166.7M	$153.3M	$74.50M
YoY Change	123.81%	341.77%	75.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.157M	$11.64M	$9.600M
YoY Change	-25.45%	406.09%	300.0%
Accrued Expenses	$8.878M	$8.831M	$3.000M
YoY Change	195.92%	341.55%	76.47%
Deferred Revenue	$475.7K	$339.3K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$25.81M	$28.76M	$15.90M
YoY Change	62.35%	432.65%	238.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$11.37K	$11.00K	$41.40M
YoY Change	-99.97%	-99.95%	223.44%
Total Long-Term Liabilities	$11.37K	$11.00K	$41.40M
YoY Change	-99.97%	-99.95%	132.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.81M	$28.76M	$15.90M
Total Long-Term Liabilities	$11.37K	$11.00K	$41.40M
Total Liabilities	$54.05M	$58.28M	$57.40M
YoY Change	-5.84%	111.15%	155.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$133.8M	-$120.0M
YoY Change
Common Stock	$1.788K	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$112.7M	$95.02M	$17.09M
YoY Change
Total Liabilities & Shareholders Equity	$166.7M	$153.3M	$74.50M
YoY Change	123.81%	341.77%	75.71%

Cashflow Statement

Concept	2020 Q4	2020 Q2	2019 Q4
OPERATING ACTIVITIES
Net Income	-$9.525M	-$3.150M	-$214.2K
YoY Change	4345.8%	-78.32%	-95.4%
Depreciation, Depletion And Amortization	$18.00K	$2.470M	$1.290M
YoY Change	-98.6%	225.0%	92.54%
Cash From Operating Activities	-$2.930M	-$7.760M	-$6.100M
YoY Change	-51.97%	123.63%	41.53%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$30.00K	-$50.00K	-$4.910M
YoY Change	-99.39%	-44.44%	792.73%
Cash From Investing Activities	-$30.00K	-$50.00K	-$4.910M
YoY Change	-99.39%	-44.44%	776.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$29.60M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	27.08M	-6.370M	9.260M
YoY Change	192.44%	-5408.33%	-50.48%
NET CHANGE
Cash From Operating Activities	-2.930M	-7.760M	-6.100M
Cash From Investing Activities	-30.00K	-50.00K	-4.910M
Cash From Financing Activities	27.08M	-6.370M	9.260M
Net Change In Cash	24.12M	-14.18M	-1.750M
YoY Change	-1478.29%	312.21%	-112.65%
FREE CASH FLOW
Cash From Operating Activities	-$2.930M	-$7.760M	-$6.100M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$7.760M	-$6.100M
YoY Change		123.63%	41.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	aytu	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	19899000
	aytu	Fixed Payment Arrangements Included In Accrued Liabilities FixedPaymentArrangementsIncludedInAccruedLiabilities	1050000
	aytu	Fixed Payment Arrangements Included In Accrued Liabilities FixedPaymentArrangementsIncludedInAccruedLiabilities
	aytu	Gain Loss From Change In Fair Value Of Cvr GainLossFromChangeInFairValueOfCVR	-899987
CY2020Q4	aytu	Accrued Productrelated Fees AccruedProductrelatedFees	2332000
CY2020Q2	aytu	Accrued Productrelated Fees AccruedProductrelatedFees	2471000
CY2020Q4	aytu	Accrued Program Related Liabilities AccruedProgramRelatedLiabilities	1386000
CY2020Q2	aytu	Accrued Program Related Liabilities AccruedProgramRelatedLiabilities	959000
	aytu	Acquisition Costs Included In Accounts Payable AcquisitionCostsIncludedInAccountsPayable
	aytu	Acquisition Costs Included In Accounts Payable AcquisitionCostsIncludedInAccountsPayable	59014
	aytu	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	842
	aytu	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod
	aytu	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	403760
CY2020	aytu	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P2Y
	aytu	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P1Y237D
	aytu	Contingent Consideration In Accounts Payable ContingentConsiderationInAccountsPayable
	aytu	Contingent Consideration In Accounts Payable ContingentConsiderationInAccountsPayable	3430
CY2020Q4	aytu	Contingent Value Rights Liabilities Current ContingentValueRightsLiabilitiesCurrent	977475
CY2020Q2	aytu	Contingent Value Rights Liabilities Current ContingentValueRightsLiabilitiesCurrent	839734
CY2020Q4	aytu	Contingent Value Rights Liabilities Noncurrent ContingentValueRightsLiabilitiesNoncurrent	5494112
CY2020Q2	aytu	Contingent Value Rights Liabilities Noncurrent ContingentValueRightsLiabilitiesNoncurrent	4731866
CY2020Q4	aytu	Credit Card Liabilities CreditCardLiabilities	712000
CY2020Q2	aytu	Credit Card Liabilities CreditCardLiabilities	510000
	aytu	Gain Loss From Change In Fair Value Of Cvr GainLossFromChangeInFairValueOfCVR
CY2020Q4	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration
CY2019Q4	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration	5199806
	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration
	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration	5199806
CY2020Q4	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-257559
CY2019Q4	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt
	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-257559
	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt
	aytu	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent
	aytu	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-3990
	aytu	Increase Decrease In Fixed Payment Arrangements IncreaseDecreaseInFixedPaymentArrangements
	aytu	Increase Decrease In Fixed Payment Arrangements IncreaseDecreaseInFixedPaymentArrangements	-216150
	aytu	Increase Decrease In Revenues Percentage IncreaseDecreaseInRevenuesPercentage	3.77
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11824560
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7001068
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5175924
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8878000
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7849855
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8877715
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	504000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	484000
	aytu	Increase Decrease In Revenues Percentage IncreaseDecreaseInRevenuesPercentage	5.21
	aytu	Inventory Swap InventorySwap	7043849
	aytu	Inventory Swap InventorySwap
CY2020Q4	aytu	Medicaid Liabilities MedicaidLiabilities	2094000
CY2020Q2	aytu	Medicaid Liabilities MedicaidLiabilities	1842000
	aytu	Proceeds From Deposits Investing Activities ProceedsFromDepositsInvestingActivities	-3923
	aytu	Proceeds From Deposits Investing Activities ProceedsFromDepositsInvestingActivities
CY2020Q4	aytu	Return Reserve ReturnReserve	1656000
CY2020Q2	aytu	Return Reserve ReturnReserve	1329000
	aytu	Warrants Issued WarrantsIssued	356139
	aytu	Warrants Issued WarrantsIssued
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001385818
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17882893
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	AYTU BIOSCIENCE, INC
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	aytu
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7157208
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	246532284
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-13831224
CY2020Q4	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	15147034
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	28667280
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	101537
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	215024216
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	165171
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	162264
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	454918
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	508059
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4008866
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1272154
CY2020Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1584580
CY2019Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	953450
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3169161
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1528567
CY2020Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3154845
CY2019Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2195528
CY2020Q4	us-gaap	Assets Assets	166742096
CY2020Q2	us-gaap	Assets Assets	152836330
CY2020Q4	us-gaap	Assets Current AssetsCurrent	92537465
CY2020Q2	us-gaap	Assets Current AssetsCurrent	74965772
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	74204631
CY2020Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	77870558
CY2020Q4	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.72
CY2019Q4	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.40
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.09
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-6.85
CY2019Q4	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-2450247
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-11255247
CY2019Q4	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	8929802
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	20541401
CY2020Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3313656
CY2019Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2411333
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3705931
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	713251
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	12573916
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	12874351
CY2020Q4	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-9525294
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11294227
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62284606
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62032642
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48081715
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62300000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48333307
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5510888
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13951299
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5783339
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2288528
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2691446
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17882893
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12583736
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17882893
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12583736
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1788
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	1259
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	475680
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	339336
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	38320000
CY2020Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	3475000
CY2020Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	3300000
CY2020Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	8300000
CY2020Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	5176000
CY2020Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	9769000
CY2020Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	8300000
CY2020Q4	us-gaap	Cost Of Revenue CostOfRevenue	5998389
CY2019Q4	us-gaap	Cost Of Revenue CostOfRevenue	606046
	us-gaap	Cost Of Revenue CostOfRevenue	9817545
	us-gaap	Cost Of Revenue CostOfRevenue	981766
CY2020Q4	us-gaap	Costs And Expenses CostsAndExpenses	20722155
CY2019Q4	us-gaap	Costs And Expenses CostsAndExpenses	8142331
	us-gaap	Costs And Expenses CostsAndExpenses	37799126
	us-gaap	Costs And Expenses CostsAndExpenses	14317631
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1057559
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	16023
CY2020Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	32981
CY2020Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18000
CY2019Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	51000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	32000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4012909
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2157540
CY2020Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
CY2019Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1830
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	1830
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.09
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.13
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2540353
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3117177
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	311000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	350000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	124000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	3000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	35000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	127000
CY2020Q4	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	61000
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	39000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12394000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9423000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6085000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3157000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4480000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	6033000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	6045000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	58093000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	58473000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	45699000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	48855000
	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9Y160D
CY2020	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9Y40D
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-112110
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	343185
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease
CY2020Q4	us-gaap	Goodwill Goodwill	28090407
CY2020Q2	us-gaap	Goodwill Goodwill	28090407
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	195000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1965271
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3456364
CY2019Q4	us-gaap	Inventory Write Down InventoryWriteDown	0
	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	55000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3136163
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2806973
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1711466
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	145467
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	136344
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-576824
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-62729
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3615662
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	132199
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2295055
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	136694
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	379337
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	171430
CY2020Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-378958
CY2019Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-446958
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1130499
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-642344
	us-gaap	Interest Paid Net InterestPaidNet	306752
	us-gaap	Interest Paid Net InterestPaidNet	3390
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5981000
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9603000
CY2020Q4	us-gaap	Inventory Net InventoryNet	6571254
CY2020Q2	us-gaap	Inventory Net InventoryNet	9999441
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	590000
CY2020Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	397000
CY2020Q4	us-gaap	Inventory Write Down InventoryWriteDown	100000
	us-gaap	Inventory Write Down InventoryWriteDown	200000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	37000
CY2020Q4	us-gaap	Liabilities Liabilities	54049428
CY2020Q2	us-gaap	Liabilities Liabilities	57821034
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	166742096
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152836330
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25813419
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	28306581
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	150000
CY2020Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	315000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24898281
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9258350
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46683
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5954635
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10900299
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9087054
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4929030
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-214247
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4305931
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-9525294
	us-gaap	Net Income Loss NetIncomeLoss	-13831224
	us-gaap	Net Income Loss NetIncomeLoss	-5143277
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3950173
CY2019Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4752848
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4699378
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4559292
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	41318
CY2020Q2	us-gaap	Notes Payable Current NotesPayableCurrent	982076
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5575121
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4967095
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9131846
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9702569
CY2020Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	90000
CY2019Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	30000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	160000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	63000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100263
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	300426
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	211056
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	725374
	us-gaap	Operating Lease Payments OperatingLeasePayments	147000
	us-gaap	Operating Lease Payments OperatingLeasePayments	63000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	310479
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	634093
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y102D
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	373000
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	249000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10598771
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	5742011
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11371
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4292781
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	741650
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1350000
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11371
CY2020Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1937476
CY2020Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	2340166
CY2020Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	9945554
CY2020Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	11171491
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	42760
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	104635
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5715089
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4500000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6081766
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29600000
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	32249652
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	10000000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89663
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	258516
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	147627
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	272727
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	2785863
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286572
CY2019Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66675
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	469437
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	144695
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	251964
CY2020Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	251592
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133841404
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120010179
CY2020Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15147034
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	28667280
CY2019Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3175236
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4615062
CY2020Q4	us-gaap	Revenues Revenues	15147000
CY2019Q4	us-gaap	Revenues Revenues	3175000
	us-gaap	Revenues Revenues	29000000
	us-gaap	Revenues Revenues	4615000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	43082
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	412691
CY2019Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6516160
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24342983
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11662603
	us-gaap	Share Based Compensation ShareBasedCompensation	962977
CY2020Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12852614
	us-gaap	Share Based Compensation ShareBasedCompensation	327435
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9095
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	67.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3187
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	76614
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	73425
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.39
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.71
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y295D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y244D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y29D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised
CY2019Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5559914
CY2019Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2019Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1057559
CY2020Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28317444
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	7087818
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	2323959
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17090240
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	95015296
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	91062746
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	112692668
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	175000
CY2020Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	175000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;margin:0pt;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent consideration, contingent value rights ("CVRs"), and fixed payment obligations at the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, those related to the determination of the fair value of equity awards, the fair value of identified assets and liabilities acquired in business combinations, the useful lives of property and equipment, intangible assets, impairment of long-lived and intangible assets, including goodwill, provisions for doubtful accounts receivable, certain accrued expenses, and the discount rate used in measuring lease liabilities. These estimates and assumptions are based on the Company's historical results and management's future expectations. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div>
CY2020Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13281904
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1753815
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12717180
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1642599

Files In Submission

Name	View Source	Status
0001437749-21-002627-index-headers.html	Edgar Link	pending
0001437749-21-002627-index.html	Edgar Link	pending
0001437749-21-002627.txt	Edgar Link	pending
0001437749-21-002627-xbrl.zip	Edgar Link	pending
aytu-20201231.xml	Edgar Link	completed
aytu-20201231.xsd	Edgar Link	pending
aytu-20201231_cal.xml	Edgar Link	unprocessable
aytu-20201231_def.xml	Edgar Link	unprocessable
aytu-20201231_lab.xml	Edgar Link	unprocessable
aytu-20201231_pre.xml	Edgar Link	unprocessable
aytu20201219_10q.htm	Edgar Link	pending
ex_218566.htm	Edgar Link	pending
ex_223935.htm	Edgar Link	pending
ex_223936.htm	Edgar Link	pending
ex_224614.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
logo_sml.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AYTU
AYTU BIOPHARMA, INC Stock $aytu

2020 Q4 Form 10-Q Financial Statement

#000143774921002627 Filed on February 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU AYTU BIOPHARMA, INC Stock $aytu

2020 Q4 Form 10-Q Financial Statement

#000143774921002627 Filed on February 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU
AYTU BIOPHARMA, INC Stock $aytu